mbc

MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC), with potential to treat tumor-induced bone disease (TIBD).

MBC-11 triethylamine has potential to treat tumor-induced bone disease (TIBD), is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC).

MBC-11 trisodium has potential to treat tumor-induced bone disease (TIBD).It is a first-in-class conjugate of the bone-targeting bisphosphonate HEDP covalently linked to the antimetabolite Ara-C.

Sapienic acid sodium is a fatty acid with variable antimicrobial activities against Gram-positive and Gram-negative bacteria found on the skin and in the oral cavity.

Sapienic acid, a fatty acid commonly found on the skin and in the mucosa, is active against Streptococcus sanguinis, Streptococcus mitis, and Fusobacterium nucleatum, with MBC values of 31.3 μg/mL, 375.0 μg/mL, and 93.8 μg/mL, respectively.

4-Methylbenzylidene camphor is an ultraviolet light blocker used in cosmetics and sunscreen preparations ,specifically UV B radiation, also has estrogenic activities.

MBCQ is an inhibitor of cGMP-specific phosphodiesterase PDE5.

TJ191 is a selective anti-cancer agent, targeting low TβRIII-expressing malignant T-cell leukemia/lymphoma cells.

hMAO-B/MB-COMT-IN-1 is a dual MAO-B/MB-COMT inhibitor with IC50s of 2.5 μΜ for hMAO-B and 3.84 μΜ for MB-COMT. hMAO-B/MB-COMT-IN-1 protects cells from oxidative damage and can be utilized in neurodegenerative disease research, such as Parkinson's Disease (PD) [1].

hMAO-B/MB-COMT-IN-2 is a dual inhibitor of MAO-B/MB-COMT with IC50s of 4.27 μM and 2.69 μM for hMAO-B and MB-COMT, respectively. hMAO-B/MB-COMT-IN-2 protects cells from oxidative damage and can be used in neurodegeneration disease research, such as Parkinson's Disease (PD) [1].

6-MB-cAMP is a membrane-permeable analog of cAMP and functions as a cAMP agonist.

2'-O-MB-cGMP (2′-O-Monobutyryl-cGMP) sodium functions as an inhibitor of cyclic GMP-specific phosphodiesterases (cyclic GMP-specific phosphodiesterase), exhibiting an IC50 value of 35 µM. This compound effectively inhibits the hydrolysis of phosphodiesterases that use cAMP or cGMP as substrates in a Ca2+-dependent manner.

2'-O-MB-cAMP (2'-O-Monobutyryl cyclic AMP) sodium serves as an active precursor of cyclic AMP.

4-Chlorosalicylic acid (4-Chloro-2-hydroxybenzoic acid, 4-chloro salicylic acid) is antimicrobial compositions comprising a metal salt and a benzoic acid analog.

Thiophanate-Methyl (TM), a methyl benzimidazole carbamate (MBC) fungicide,

Carbonic anhydrase inhibitor28 (Compound 11) serves as an inhibitor for the Pseudomonas aeruginosa carbonic anhydrase. It exhibits antibacterial activity, with minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values of 0.5 and 1 μg/mL, respectively, against P. aeruginosa. Carbonic anhydrase inhibitor28 is utilized in research focused on anti-infection applications.

Antiangiogenic agent 8 (Compound 3m) functions as both an antibacterial agent and an antiangiogenic compound. It shows minimum inhibitory concentrations (MIC) of 16, 8, 4, 16, and 8 μg/mL against E. coli, P. aeruginosa, B. subtilis, S. aureus, and C. glabrata, respectively, with minimum bactericidal concentrations (MBC) ranging from 32 to 64 μg/mL. This compound holds potential for applications in infection control and cardiovascular disease research.

MRSA/VRE-IN-1 (Compound 3e) is an inhibitor targeting methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), with MIC/MBC values of 3.6/7.3 µM for VRE and 7.3/14.6 µM for MRSA. It is applicable in research focused on anti-infection studies.

Anti-MRSA agent 31 (Compound 6) is an agent effective against methicillin-resistant Staphylococcus aureus (MRSA), with a minimum inhibitory concentration (MIC) of 97 μg/mL and a minimum bactericidal concentration (MBC) of 781.25 μg/mL. It exhibits potent antibacterial activity and significant inhibitory action on penicillin-binding protein 2a (PBP2a).

Antibacterialagent 282 (Compound CP7) is a selenium-containing derivative of Ciprofloxacin that serves as an antibacterial agent. It exhibits significant activity against both Gram-positive and Gram-negative bacteria, with MICs ranging from 0.1-1.56 μg/mL and 0.1-3.13 μg/mL, respectively (MBCs are 0.2-1.56 μg/mL and 0.39-12.5 μg/mL). Additionally, Antibacterialagent 282 effectively disrupts and prevents P. aeruginosa biofilm formation and significantly inhibits the DNA gyrase of E. coli.

Anbenitamab (KN-026) is a bispecific antibody targeting extracellular domains II and IV of human HER2, blocking both ligand-dependent and independent signaling pathways. Its IgG1 Fc fragment activates FcRγIIIa, triggering strong antibody-dependent cell-mediated cytotoxicity (ADCC) and suppressing tumor cell growth. Anbenitamab shows promise for research in HER2-positive metastatic breast cancer (MBC) [1][2].

DNA Gyrase-IN-9 (compound 4j), an antibacterial agent, selectively targets DNA gyrase and exhibits a minimum inhibitory concentration (MIC) of 0.5-2 µg/mL for Gram-positive bacteria inhibition and a minimum bactericidal concentration (MBC) of 2-8 µg/mL for Gram-positive bacteria eradication. Notably, this compound hinders DNA gyrase activity in Staphylococcus aureus with an IC50 of 6.29 µg/mL [1].

Vibralactone B shows antibacterial activity, it can inhibit significantly the growth of E. coli and Pseudomonas aeruginosa, with MBC values of 50 and 100 ug/mL, respectively.

Crabrolin is a 13-peptide that can be extracted from the venom of the European hornet (Vespa crabro). Its minimum inhibitory concentration/minimum bactericidal concentration (MIC/MBC) values against Staphylococcus aureus (S. aureus) (NCTC 10788), methicillin-resistant Staphylococcus aureus (MRSA) (NCTC 12493), and Enterococcus faecium (E. faecium) (NTCC 12697) are 2/2, 16/64, and 4/8 μM, respectively.